Antibody Drug Conjugate Linker via Secondary Nitrogen Carbamate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face limitations in linker design, which affects both efficacy and safety due to restricted chemical functionalities available for forming linkages between the linker and drug, restricting the types of drugs that can be used.
Innovation Solution
The development of methods to conjugate antibodies to biologically active molecules through linkers covalently bound to a secondary nitrogen, using compounds with a carbamate formed by a secondary nitrogen on the biologically active molecule and an oxycarbonyl on the linker moiety, allowing for a wide variety of antibodies and engineered antibodies to be conjugated, thereby expanding the range of possible ADCs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional linker design is used in ADCs, then the chemical functionality for forming linkages is limited, but this restriction simplifies the design process. However, this limitation reduces the versatility and range of drugs that can be used in ADCs
Solution Approach 1:
The patent develops a universal linker platform with multiple chemical functionalities that can conjugate to various drugs through different mechanisms (amine reaction, thiol reaction, click chemistry). This single linker design serves multiple functions: it provides stable systemic circulation, enables intracellular release, and accommodates diverse drug structures, thereby increasing versatility without proportionally increasing complexity
Solution Approach 2:
The patent modifies linker parameters by incorporating specific functional groups (oxycarbonyl, carbamate, secondary nitrogen) that change the chemical reactivity and bonding characteristics. These parameter changes enable the linker to form stable bonds during circulation while allowing controlled release intracellularly, expanding drug compatibility without requiring completely new linker designs for each drug
2Reliability
If the linker provides sufficient stability during systemic circulation, then safety is improved, but this stability may prevent rapid intracellular release of the drug. However, the patent's linker design achieves both stability and rapid release
Solution Approach 1:
The linker exhibits dynamic behavior by maintaining a stable configuration during systemic circulation through optimized bond strengths and spatial arrangement, then transitioning to a reactive state intracellularly through pH changes or enzymatic triggers. The secondary nitrogen and carbamate groups facilitate this dynamic transition, allowing the linker to adapt its stability characteristics based on the environmental context
Solution Approach 2:
The carbamate functional group acts as an intermediary between the stable external environment and the reactive intracellular environment. It forms stable bonds with drugs during circulation but serves as a cleavable linkage intracellularly, mediating the transition from stable transport to rapid release without requiring extreme conditions at either stage
3Reliability
If tumor cells are targeted with specific drugs, then treatment efficacy is improved, but tumor cells can become resistant through mutation. However, expanding drug options through varied linker chemistry may help overcome resistance
Solution Approach 1:
The versatile linker platform enables the same antibody framework to be paired with multiple different drug payloads through standardized conjugation chemistry. This universality allows clinicians to switch between different drug-linker combinations when resistance develops, maintaining treatment efficacy without requiring new antibody developments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the stability of ADCs during systemic circulation while enabling rapid and efficient intracellular release of the drug, improving targeting specificity and reducing off-target toxicity.
Implementation Method 1
conjugate antibodies to biologically active molecules through linkers covalently bound to a secondary nitrogen, using compounds with a carbamate formed by a secondary nitrogen on the biologically active molecule and an oxycarbonyl on the linker moiety
Data Source
AI summary
The subject matter described herein is directed to methods of preparing certain antibody-drug conjugates (ADCs) wherein the antibody is linked to the drug through a linker, wherein the drug contains a heteroaryl group having a secondary nitrogen, and the linker is attached to the drug via the secondary nitrogen. The resulting conjugates are useful in treating various diseases and conditions.